Components of mRNA Technology “Could Lead to Significant Adverse Events in One or More of Our Clinical Trials,” says Moderna

By the Children's Health Defense Team

A dozen Covid-19 vaccines are undergoing clinical trials and several of the U.S. contenders—Moderna, Pfizer/BioNTech and Arcturus Therapeutics—are deploying never-before-approved messenger RNA (mRNA) technology, an experimental approach designed to turn the body’s cells into viral-protein-making factories. This technology relies on a nanoparticle-based “carrier system” containing a synthetic chemical called polyethylene glycol (PEG).

A 2016 study found roughly 70% of Americans may already be sensitized to PEG and investigators who once assumed that the polymer was largely “inert” are warning about adverse immune responses that include “probably underdiagnosed” life-threatening anaphylaxis (also called hypersensitivity). FDA approval of an mRNA vaccine for Covid-19 could be potentially disastrous.

Moderna documents and publications indicate that the company is well aware of these safety risks but is more concerned with its bottom line.

Dr. Fauci’s Double Standards: Polarizing the Nation on Hydroxychloroquine

By Robert F. Kennedy, Jr., Chairman, Children’s Health Defense

On one hand, there’s Hydroxychloroquine (HCQ). Been in use 60+ years, patent is long expired…pills cost 30 cents and reportedly its relative, chloroquine, is effective in preventing the spread of SARS CoV in cell culture. On the other hand, there’s vaccines (including the Moderna vaccine for which Dr. Fauci’s agency co-owns the patent and has invested $500 million in taxpayer dollars.) Developed at a blistering pace, with limited testing and no manufacturer's liability.

I don’t know if hydroxychloroquine (HCQ) is effective against COVID, but it’s disturbing that I, like many other Americans, feel that we won’t learn the truth from Dr. Fauci.

Maryland’s $145 Million Cervical Cancer Policy Fail

By Josh Mazer, (Originally published in Eye on Annapolis)

I have been following Maryland’s HPV vaccine policy very closely since 2018, when our children became eligible to receive Merck’s controversial, liability free HPV vaccine. I was confused by the state-sponsored hard sell put on my family to buy the shot. My concerns about state policies have increased as more recent data has emerged.

In 2007 Maryland’s cervical cancer policy changed with HB 1049/SB 774, Task Force on the HPV Vaccine, which made Merck’s Gardasil vaccine the new centerpiece—the proven test and educate strategy was abandoned. Since then, cervical cancer incidence is up 8%.

Maryland’s cervical cancer policy has reached a crisis point.

The Fix Was In: Latest ACIP Meeting’s Public Comments Featured a Who’s Who Among Vaccine Promoters

By Kari Bundy, CHD Communications Assistant

The Advisory Committee on Immunization Practices (ACIP) held a special (virtual) meeting on Wednesday July 29 to address considerations for a COVID-19 vaccination. Like many parents and concerned citizens, I was interested in hearing ACIP’s discussions on vaccine implementation, but because I have serious concerns about this vaccine, I also attempted to register to comment during the meeting. I ultimately never received an email confirming this and assumed I simply had not been chosen to speak.

On Wednesday, as public comment began, I noticed that, one after another, the people who stepped up to speak were enthusiastically pro-vaccine in their statements and in fact spent much of their time complimenting the CDC and the ACIP members in particular for their noble efforts. I began to wonder if the event and it’s chosen “random speakers” had been orchestrated to show the public a one-sided conclusion for mandatory COVID-19 vaccination recommendations.

By Kim Roberts, The Texan

The number of doctors publicly supporting the use of hydroxychloroquine for early treatment or prevention is growing.

Recently, Dr. Kevin R. Wheelan, chief of cardiology at Baylor Heart and Vascular Hospital in Dallas and Dr. Peter McCullough, a clinical cardiologist and professor at the Texas A&M School of Medicine, issued a letter supporting the emergency use authorization (EUA) of hydroxychloroquine for outpatient treatment and prophylaxis for COVID-19.